SUMMIT Results: Tirzepatide for HFpEF and Obesity

Heart Failure Risk Reduction

Weight Loss at 52 Weeks

15.7% body weight reduction (efficacy estimand)

13.9% body weight reduction (treatment-regimen estimand)

Heart Failure Symptoms (KCCQ-CSS) Efficacy Estimand

Study Details

Participants: 731

Median follow-up: 104 weeks